For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 2 Key points 1. Extracellular nuclear proteins histone H4 and HMGB1 are highly proinflammatory cytokines.
Introduction
The normally chromatin-associated nuclear proteins, histones (in particular histone H4, H4) and high mobility group box 1 (HMGB1) can act as extracellular cytokines in the pathogenesis of inflammatory disorders. [1] [2] [3] They can be released into intravascular spaces by cells of the innate immune system, damaged tissues and necrotic cells in response to bacterial endotoxin and/or trauma. [2] [3] [4] Activated neutrophils release their nuclear contents--including histones--as extracellular traps to bind and neutralize invading bacteria. 5 Elevated H4 and HMGB1 plasma levels correlate with poor prognosis and high mortality in patients with severe sepsis and other inflammatory disorders such as cancer. 1, 3, 6 Proinflammatory signaling cascades initiated by nuclear cytokines through the receptor for advanced glycation end products (RAGE) on platelets and vascular endothelial cells are pivotal in procoagulant and proinflammatory responses. [7] [8] [9] [10] TLR4 signaling mediated by bacterial membrane lipopolysaccharides (LPS) derived from gram-negative bacteria is implicated in the pathogenesis of severe sepsis. 2, 3, 11, 12 Interestingly, LPS potently stimulates HMGB1 and H4
release by endothelial cells, suggesting that LPS can amplify proinflammatory responses indirectly through other pattern recognition receptors including RAGE. 10, 13 Consistent with their role in the pathogenesis of severe sepsis, pharmacological inhibition of either H4 or HMGB1 can improve survival in experimental models of endotoxemia, while infusion of either H4 or HMGB1 into mice is highly cytotoxic, causing death from multiple organ failure. [1] [2] [3] Another proinflammatory mediator attracting much attention recently is inorganic polyphosphate (polyP). 14 Platelets are rich sources of HMGB1 and polyP, which are stored in
For personal use only. on . by guest www.bloodjournal.org From 4 dense granules and upon platelet activation, both molecules are secreted into circulation. 14, 15 Whether polyP and HMGB1 can be secreted as a complex by activated platelets is not known.
PolyP stimulates both procoagulant and proinflammatory pathways in vitro and in vivo.
14, 16 We reported that polyP containing 70 phosphates (polyP-70), similar to the size in platelets, elicits proinflammatory responses by activating NF-κB in vascular endothelial cells. 17 The mechanism of polyP-induced inflammation is poorly understood. PolyP can evoke Ca 2+ signals through P2Y 1 purinergic receptors (in particular P2Y 1 ) in astrocytes, 18 but whether polyP also triggers proinflammatory signaling in endothelial cells through the same pathway is unknown.
Furthermore, the possibility that anionic polyP modulates signaling activities of cationic proteins, histones and HMGB1, during inflammation has not been investigated.
Here, we report the synergistic effect of polyP-70 on proinflammatory functions of H4 and HMGB1, both in cellular and animal models. We show that polyP-70 binds to both proteins with high affinity to dramatically potentiate their proinflammatory signaling effects. By employing siRNA knockdowns, pharmacological inhibitors and extracellular domains of TLR2, TLR4, RAGE and P2Y 1 as competitive inhibitors, we demonstrate polyP-70 amplifies H4-and HMGB1-mediated proinflammatory signaling pathways through interaction with two receptors, RAGE and P2Y 1 , thereby eliciting a Ca 2+ signal and activating NF-κB in endothelial cells. Interestingly, an HMGB1 concentration of 2-3 nM in complex with sub-nanomolar polyP-700 (similar to the size in bacteria) elicits a robust proinflammatory response in endothelial cells. Finally, we show activated protein C (APC) potently inhibits polyP-mediated proinflammatory activity of H4 and HMGB1 in cellular and animal models.
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Materials and Methods

Reagents
PolyP-70 was a generous gift from Dr. James Morrissey (University of Illinois, Urbana).
PolyP-700 was purchased from Kerafast (USA). The P2Y 1 antagonist, MRS-2279, was purchased from Tocris (Bioscience, UK). Histone 4 (H4) was from New England Biolabs. Six weeks old male C57BL/6 mice were obtained from Jackson laboratory. The complete list of reagents is presented as Supplementary Materials.
Recombinant proteins
The recombinant forms of HMGB1 and extracellular domains of all receptors (soluble receptors) TLR2 (sTLR2), TLR4 (sTLR4), RAGE (sRAGE) and P2Y 1 (sP2Y 1 ) were expressed in E. coli using SUMO expression/purification system with a His tag and purified using a combination of Ni-Sepharose and Hi-Trap Q HP column chromatography as described in Supplementary Materials.
Cell culture
Primary HUVECs were obtained from Cambrex Bio Science Inc and cultured as described. 13 Transformed human umbilical vein endothelial cell line EA.hy926 (kindly provided by Dr. C. Edgell from University of North Carolina at Chapel Hill, NC, USA) maintained as described. 13 For
Permeability assay
Endothelial cell permeability in response to increasing concentrations of HMGB1 (0-80 nM for 16h), H4 (0-3.5 µM for 4h), and polyP (0-50 µM for 4h) was assessed by spectrophotometric measurement of the flux of Evans blue-bound albumin across functional cell monolayer by a modified two-compartment chamber model as described. 13 Cell permeability was also measured in the presence of increasing concentrations of soluble receptors, sRAGE), sTLR2, sTLR4, sP2Y 1 , and pharmacological inhibitors thapsigargin (1 µM for 1h) and MRS-2279
(50 µM for 1h) in the absence and presence of polyP-70 using the same protocol. To investigate the effect of APC, cells were treated with APC for 3h before inducing permeability with different stimuli.
Analysis of expression of cell adhesion molecules
The cell surface expression levels of VCAM-1, ICAM-1, and E-selectin on HUVECs were measured by a whole-cell based ELISA as described. 13 Briefly, cell monolayers, which were incubated with increasing concentration of H4 (0-3.5 µM, 4h), HMGB1 (0-40 nM, 16h), and polyP (0-50 µM, 4h), were fixed in 1% paraformaldehyde. After washing 3 times, mouse antihuman mAbs to VCAM-1, ICAM-1 and E-selectin were added overnight at 4 o C. Cells were then washed and peroxidase-conjugated anti-mouse IgG (Sigma) was added for 1h. Cells were washed again and developed using o-phenylenediamene substrate (Sigma).
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Caspase-8 assay
The activity of caspase-8 was measured using a colorimetric kit (Genescript) according to the manufacturer's instruction. Briefly, after treating cells with polyP-70 (2.5 µM) in complex with either HMGB1 (10 nM) or H4 (0.44 µM), they were lysed (50 mM HEPES, pH 7.5, 100 mM NaCl, 0.1% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate [CHAPS], 1 mM dithiothreitol, 0.1 mM EDTA) and 50 µL of the cell lysate was incubated for 5 min on ice, and then centrifuged at 10,000 × g for 10 min at 4°C. Supernatants were incubated with the caspase-8 specific Ac-LEHD-pNA substrate for 4h in the dark and the enzyme activity was measured at 405 nm.
NF-κB activation
After incubating endothelial cells with different stimuli (HMGB1, H4 and polyP-70) as described above, cells were lysed with the lysis buffer, supplemented with protease and phosphatase inhibitor cocktail (Thermo Scientific Pierce, Rockford, IL, USA). The lysate was clarified by centrifugation at 13,000 × g for 10 min at 4 °C and the protein content was measured using a protein assay kit (Bio-Rad, Richmond, CA, USA). The protein sample was boiled in SDS loading buffer, separated on a 10% SDS denaturing gel and transferred to a polyvinylidene difluoride (PVDF) membrane followed by its blocking for 2h in TBST buffer (20 mM Tris-HCl, 100 mM NaCl, pH 7.5, 0.1% Tween 20) containing 5% non-fat milk. Western immunoblotting was conducted using primary and secondary antibodies and then developed with Enhanced Chemiluminescence (ECL) reagents. 
In vivo permeability and leukocyte migration assays
Six weeks old male C57bBl/6 mice were used for in vivo studies after a 5-day acclimatization period. All animals were treated in accordance with the Guidelines for Care and Use of Saint Louis University. The vascular permeability assay was carried out according to previously described methods. 17 Briefly, 1% Evans blue dye solution in normal saline was injected intravenously (i.v.) to each mouse, immediately followed by an intraperitoneal (i. For personal use only. on . by guest www.bloodjournal.org From For assessing the leukocyte migration, animals were intraperitoneally injected with above concentrations of the stimuli dissolved in normal saline. Four hours later, mice were sacrificed and the peritoneal surfaces were washed with 5 mL of normal saline. Next, 20 µL of peritoneal fluid was mixed with 0.38 mL of Turk`s solution (0.01% crystal violet in 3% acetic acid) and the number of leukocytes was counted under a light microscope. Moreover, to investigate the protective effect of APC, recombinant APC (0.2 µg/g of body weight) was injected intravenously 2h before the injection of indicated concentrations of inflammatory mediators. In these studies, CMC-Na (1.5%) was administrated to mice as a positive control for leukocyte migration as described. 17 All measurements in mice were performed for three mice in each group of the study.
Statistical analysis
Data were expressed as means ± S.D. from at least three independent experiments.
Group data were compared using analysis of variance (ANOVA) followed by the Bonferroni post-hoc tests (for comparisons among three or more groups) or Student's t-test, as appropriate.
A p value of < 0.05 was considered statistically significant. (Fig. 1d,e) . Similarly, an H4 concentration (0.44 µM, ~5 µg/mL) having no signaling activity alone (Fig. 1b) induces a potent barrier-disruptive effect in the presence of 2.5 µM polyP-70 (Fig. 1f) . To test whether polyP-70 directly binds to nuclear cytokines, we monitored Fig. S4a,c) . These results suggest polyP-70 binds to both nuclear proteins with high affinity to promote their proinflammatory functions.
RAGE mediates polyP-enhanced barrier-disruptive effect of HMGB1 and H4
Proinflammatory signaling by HMGB1 and H4 is thought to be mediated through pattern recognition receptors, RAGE, TLR2 and TLR4. 7-13, We evaluated the contribution of each receptor to polyP-mediated proinflammatory signaling by HMGB1 and H4 using recombinant extracellular domains of RAGE, TLR2 and TLR4 as competitive inhibitors of nuclear cytokine signaling in permeability assays. Recombinant proteins were purified to reasonable homogeneity ( Supplementary Fig. S1 ). The RAGE extracellular domain (sRAGE) potently inhibits HMGB1 and H4 signaling in endothelial cells ( Fig. 1g-j ). An sRAGE concentration of only ~2 molar in excess of HMGB1 or H4 effectively inhibits barrier-disruptive effects of both nuclear cytokines in the absence of polyp-70 ( Fig. 1g,h ), but sRAGE inhibition is not as efficient in the presence of polyP-70 (Fig. 1i,j) . Interestingly, while soluble forms of both TLR2 and 4 (sTLR2 and sTLR4) are equally effective in inhibiting HMGB1 signaling (Supplementary Fig.   S3a ), neither protein competes with HMGB1 or H4 signaling in the presence of polyP-70
( Supplementary Fig. S3b,c) , suggesting polyP-70 primarily binds to RAGE to promote the proinflammatory signaling by nuclear proteins. Supporting this hypothesis, we found sRAGE binds to polyP-70 with a dissociation constant of 100 nM, whereas neither sTLR2 nor sTLR4 exhibits detectable affinity for polyP-70 (Supplementary Fig. S4d ).
PolyP-70 promotes CAM expression and apoptosis by HMGB1 and H4 through RAGE
Both HMGB1 and H4 induce expression of cell adhesion molecules ICAM-1, VCAM-1 and E-selectin on endothelial cells (Fig. 2a,b) . PolyP-70 potently promotes HMGB1-and H4-mediated expression of CAMs (Fig. 2c,d ). Thus, a polyP-70 concentration (2.5 µM) exhibiting no signaling function by itself dramatically up-regulates expression of all three CAMs by low concentrations of nuclear cytokines that are also inactive by themselves (10 nM HMGB1 and 0.44 µM H4) (Fig. 2c,d ). Consistent with RAGE being the primary receptor for HMGB1 and H4
signaling, sRAGE effectively inhibits polyP-70-mediated induction of CAM expression by both nuclear cytokines (Fig. 2e-g ). sRAGE also inhibits the pro-apoptotic effect of polyP-70-mediated HMGB1 and H4 as evidenced by inhibiting caspase-8 activation by nuclear cytokines (Fig. 2h) .
These proinflammatory responses appear to be mediated through polyP-70 promoting NF-κB activation by nuclear cytokines (Fig. 2i,j) .
PolyP-70 induces Ca 2+ signaling in endothelial cells through P2Y 1 PolyP mediates astrocyte communication through the P2Y 1 receptor and release of Ca 2+ from internal stores. 18 We took four different approaches to determine whether proinflammatory signaling by polyP-70 occurs through the same mechanism. First, we tested the activity of the potent Ca 2+ pump inhibitor thapsigargin in endothelial cell permeability induced by polyP-70, 1 3 HMGB1 and H4. Thapsigargin blocks intracellular signaling induced by all three stimuli both individually and in combination with polyP-70 (Fig. 3a) . Second, we conducted nuclear cytokinemediated permeability assays using the P2Y 1 antagonist MRS-2279. 18 MRS-2279 inhibits the barrier-disruptive activity of polyP-70 (50 µM) as well as polyP-70 (2.5 µM)-mediated barrierdisruptive effects of H4 (0.44 µM) and HMGB1 (10 nM) but not the effect of either H4 (3.5 µM)
or HMGB1 (40 nM) alone (Fig. 3b) . Since polyP-70 signals through both RAGE and P2Y 1 , MRS-2279 only partially inhibits polyP-70 signaling (Fig. 3b) . Third, we expressed and purified the 51-residue P2Y 1 extracellular domain (sP2Y 1 ) from E. coli and evaluated its competitive effect in signaling assays. sP2Y 1 has no competitive effect on HMGB1 signaling and only partially inhibits polyP-70 signaling (Fig. 3c,d ), confirming the inference polyP-70 signals through both RAGE and P2Y 1 , that the effect is additive and blocking the latter receptor only partially inhibits polyP-70 signaling. In contrast, sP2Y 1 effectively inhibits polyP-mediated signaling of both HMGB1 and H4, suggesting polyP interaction with P2Y 1 is essential in promoting nuclear cytokine signaling. sP2Y 1 effectively inhibits polyP-mediated nuclear cytokines induction of VCAM and E-selectin (Fig. 3e,f) . These results clearly suggest proinflammatory signaling of these molecules, at low concentrations, requires polyP-70 interaction with P2Y 1 . Results presented below in the fourth approach, P2Y 1 knockdown, further confirm this hypothesis.
PolyP-70 promotes proinflammatory effects of HMGB1 and H4 through P2Y 1 and RAGE
Competitive inhibitors of RAGE (sRAGE) and P2Y 1 (MRS-2279 and sP2Y 1 
proinflammatory activities of both polyP and polyP-mediated nuclear cytokines, suggesting polyP-70 interacts with both receptors. We tested polyP-70-, HMGB1-and H4-mediated signaling in endothelial cells knocked-down for RAGE and P2Y 1 , using barrier permeability ( Fig.   4a-e) and CAM expression assays (VCAM-1 or E-selectin; Fig. 4f-j) . In both assays, knockdown of RAGE but not of P2Y 1 inhibits proinflammatory signaling by HMGB1 (40 nM) and H4 (3.5 µM)
in both permeability (Fig. 4a,b) and CAM assays (Fig. 4f,g ). By contrast, knockdown of either P2Y 1 or RAGE partially inhibits proinflammatory signaling when polyP-70 is at high concentration by itself (50 µM, Fig. 4c,h ) or at low concentration (2.5 µM) together with low HMGB1 (10 nM) or H4 (0.44 µM) concentrations (Fig. 4d,e) . Double knockdown nearly completely inhibits polyP-mediated proinflammatory effects of both cytokines (Fig. 4i,j) . These 
APC inhibits proinflammatory effects of polyP-70, HMGB1 and H4 in vitro and in vivo.
APC is a natural anticoagulant with cytoprotective and antiinflammatory effects both in vitro and in vivo. 10, [19] [20] [21] APC abrogates polyP-70-mediated proinflammatory signaling by HMGB1
and H4 in both permeability (Fig. 5a,b) and CAM expression assays (Fig. 5c-e) . HMGB1 and H4 combined with low polyP-70 concentrations were injected intraperitoneally into mice, followed by measuring vascular permeability based on extravasation of BSA-bound Evans blue dye from plasma into the peritoneal cavity. Minimum concentrations of 10 µg/g (H4)
(HMGB1), and 150 µg/g (polyP-70) are required to induce vascular permeability in mice ( Fig. 5f-h ). PolyP-70 dramatically potentiates proinflammatory effects of nuclear cytokines; low polyP-70 concentrations (35 µg/g) dramatically increase endothelium leakiness induced by low HMGB1 (1 µg/g) or H4 (2.5 µg/g) concentrations (Fig. 5i) that are inactive when administered alone.
Similarly, polyP-70 markedly enhances HMGB1-and H4-mediated binding of leukocytes to the vascular endothelium and their subsequent migration to the peritoneal cavity (Fig. 5j-m) . The intravenous administration of APC (0.2 µg/g) abrogates proinflammatory effects of polyP-70 + nuclear cytokines in both in vivo assays (Fig. 5i,m) . Previous results have indicated that APC can exert a protective activity through the cleavage of H4. 1 While a protective effect from the APC cleavage of H4 cannot be ruled out in this model, nevertheless, the APC cleavage of HMGB1 cannot account for its protective mechanism since we have demonstrated that a high concentration of APC is unable to cleave HMGB1.
13
Longer chain polyP-700 dramatically promotes proinflammatory signaling by HMGB1 and
H4
Finally, we tested the proinflammatory effect of polyP-700, which can be synthesized by bacteria and released to circulation during infection. 14,22 Strikingly, we found ~40-fold lower polyP-700 concentration was sufficient to dramatically potentiate proinflammatory signaling by both HMGB1 and H4 in the permeability assay ( Fig. 6a-e) . Thus, in contrast to 2. 5 nM, 0.067-0.125 µg/mL) ( Fig. 6d) and H4 (88 nM, 1 µg/mL) (Fig. 6e) concentrations in this assay. Thus, longer chain polyP molecules secreted by bacteria could dramatically up-regulate inflammation during infection. Each polyP-700 monomer binds to 5 HMGB1, possibly explaining its dramatic proinflammatory effect (Supplementary Fig. S4b ). These findings may have important ramifications for the mechanism of polyP-mediated amplification of inflammatory signaling responses during bacteria-induced severe sepsis.
Discussion
We report for the first time that polyP binds nuclear cytokines HMGB1 and H4 to dramatically amplify their proinflammatory signaling through two cell surface receptors, RAGE APC was used for over a decade to treat severe sepsis before being withdrawn due to its lack of mortality-reducing effect in a recent clinical trial. 26, 27 Our results suggest APC can effectively inhibit polyP-70-mediated proinflammatory signaling elicited by nuclear cytokines in both cellular and animal models. This suggests APC can exert a protective effect through inhibition of RAGE signaling, though a high concentration of APC is required to achieve an optimal effect. Given the bleeding side effect of high APC concentrations, APC derivatives lacking anticoagulant activity but possessing normal antiinflammatory activity will be required to assess the therapeutic potential of APC in severe inflammatory disorders. 20, 28 We propose a mechanism through which binary complexes of polyP with either HMGB1 or H4 initiates proinflammatory signaling in endothelial cells. The requirement for P2Y 1 signaling at low polyP concentrations suggests the HMGB1/H4-loaded polyP binding to the P2Y 1 receptor is associated with increased affinity of nuclear cytokines for their specific cell surface receptor, RAGE, through a bridging mechanism (Fig. 7) . We propose polyP bridging stabilizes dimeric or oligomeric forms of RAGE, facilitating the receptor clustering required for RAGE signaling. initiating downstream signaling. 7 PolyP-mediated bridging also increases ligand density on the cell surface, thereby amplifying the signal. Receptor stabilization by bridging can induce a positive feedback loop, thereby increasing expression of RAGE and further amplifying signaling.
The observation that a near-equimolar concentration of sRAGE effectively inhibits the signaling of HMGB1 in the absence of polyP-70 while a greater than 100-fold excess of sRAGE is required to inhibit polyP-mediated signaling by HMGB1 is consistent with receptor bridging of polyP through P2Y 1 playing a key role in clustering and amplification of RAGE signaling. We discovered this mechanism of polyP-mediated RAGE signaling occurs more efficiently with longer chain polyP-700 that may be released during bacterial infection. 14 Complement-mediated bacterial lysis may result in the release of longer chain polyP molecules that can bind many more nuclear cytokines, thereby dramatically amplifying proinflammatory responses through receptor bridging and clustering. It should be noted that DNA-bound nuclear cytokines have been reported to require TLR9 for eliciting effective proinflammatory signaling responses through RAGE in dendritic cells and B cells.
29,30
Further studies are required to determine whether TLR9 makes a similar contribution to polyP-mediated nuclear cytokine signaling through RAGE in endothelial cells.
These findings may have major implications for the mechanism of polyP-mediated systemic inflammatory responses during severe sepsis and how bacterial infection may overwhelm the immune system. Based on the data presented above we hypothesize that minute quantities of bacterial polyP can function as a sponge to concentrate highly proinflammatory nuclear cytokines (expected to be abundant in circulation during inflammation
and coagulation) on cell surfaces of vascular and innate immune systems, thereby activating RAGE receptors by clustering and stabilizing them by bridging. This uncontrollable and devastating immune response may explain the characteristic high rate of rapid death in severe sepsis and difficulties in devising effective strategies to dampen such an uncontrolled inflammatory response. Our proposed mechanism points to novel therapeutic targets for the treatment of acute and chronic proinflammatory complications including severe sepsis.
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